Skip to main content Skip to main navigation menu Skip to site footer


Mantled by discrimination and exclusion, HIV/AIDS became a major epidemic of present-day globalization. Access to antiretroviral therapy (ART) and numerous preventative measures have resulted in reduced mortality and morbidity rates.1 However, the burden of disease associated with HIV infection remains tremendous. Total number of people living with HIV in 2016 were 36.7 million. PrEP is an effective additional prevention strategy at trial settings. Decision to adopt PrEP as a public health intervention must be made based on the need and capacity of current systems. Instead of allocating substantial resources for PrEP, the limited resources could be wisely allocated to scale-up the existing prevention strategies including access to ART, as well as to ensure equality of access of people to full-range of HIV prevention and treatment measures.


  1. UNAIDS. UNAIDS Data 2017: Joint united nations program on HIV/AIDS; 2017.
  2. Ministry of Health of Indonesia. Laporan situasi perkembangan HIV-AIDS dan PIMS di Indonesia: April-Juni 2016 [Situational analysis report on HIV-AIDS and STIs epidemic in Indonesia: April - June 2016]. Jakarta: Ministry of Health of Indonesia; 2016.
  3. WHO. Consolidated guidelines on HIV prevention, treatment, and care for key populations. Geneva: World Health Organisation; 2014.
  4. CDC. Pre-exposure prophylaxis for the prevention of HIV infection in the United States: 2014 Clinical Practice Guideline: Centre for Disease Control, Department of Health and Human Services USA; 2014.
  5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine. 2012; 367(5): 3 99-410.
  6. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381: 2083-90.
  7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine. 2010; 363(27): 2587-99.
  8. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. The New England Journal of Medicine. 2012; 367(5): 423-34.
  9. Damme LV, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among african women. The New England Journal of Medicine. 2012; 367(5): 411-22.
  10. Weaver ERN, Pane M, Wandra T, Windiyaningsih C, Herlina, Samaan G. Factors that influence adherence to antiretroviral treatment in an urban population, Jakarta, Indonesia. PLoS One. 2014; 9(9): e107543.
  11. Cohen MS, Baden LR. Preexposure prophylaxis for HIV - Where do we go from here? The New England Journal of Medicine. 2012; 367(5): 459-61.
  12. Haire B. Considering pre-exposure prophylaxis: do the pros outweigh the cons as an HIV prevention strategy? LGBT Health. 2014; 1(4): 253-5.
  13. Kenworthy NJ, Bulled N. From modelling to morals: imagining the future of HIV PrEP in Leshoto. Developing World Bioethics. 2013; 13(2): 70-8.
  14. Veloso VG, Mesquita F, Grinsztejn B. Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. Journal of the International AIDS Society. 2015; 18(3): 20010.
  15. Bourne A, Cassolato M, Wei CKT, Wang B, Pang J, Lim SH, et al. Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Malaysia: findings from a qualitative study. Journal of the International AIDS Society. 2017; 20: 21899.

How to Cite

Sutarsa, I. N. (2017). Where do we go with HIV pre-exposure prophylaxis in Indonesia?. Public Health and Preventive Medicine Archive, 5(2), 77–78.


58 186


Search Panel